Sheri Spirt
Psychiatry · New York, NYNPI 1831257591
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,725 of the $59,513 with a category attached, or 83.6%. AbbVie accounts for 91.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $14,265 and has fallen 58.5% since, to $5,922 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 410 payments — averaging $145.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$55K
- Lundbeck LLC$765
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$689
- Supernus Pharmaceuticals, Inc.$545
- Alkermes, Inc.$509
- Otsuka America Pharmaceutical, Inc.$477
- plus $2K from 14 others
What the payments were for
- Speaking & faculty fees$49,72584%
- Travel & lodging$1,7703%
- Food & beverage$8,01913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 230 | $54,669 |
| Lundbeck LLC | 43 | $765 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $689 |
| Supernus Pharmaceuticals, Inc. | 2 | $545 |
| Alkermes, Inc. | 20 | $509 |
| Otsuka America Pharmaceutical, Inc. | 23 | $477 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $425 |
| Sunovion Pharmaceuticals Inc. | 15 | $329 |
| Vanda Pharmaceuticals Inc. | 8 | $290 |
| Axsome Therapeutics, Inc. | 4 | $207 |
| Bausch Health US, LLC | 8 | $163 |
| Sage Therapeutics, LLC | 2 | $156 |
| Corium, LLC | 4 | $88 |
| Johnson & Johnson | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 1 | $39 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,513 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 15 | $252 |
| Olanzapine | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.